News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Three Penn I-Corps Teams Participated in State-wide Pitch Event
Three Penn I-Corps teams participated in the SmartTech Tournament on April 10 and 11, 2025 as part of the Invent Penn State Venture & IP Conference.
Penn I-Corps Spring 2025 Cohort Concludes Successfully
PCI is delighted to announce graduation of its Spring 2025 Penn I-Corps cohort, which comprised ten teams drawn from participants across Penn.
AI Across Disciplines Event Highlights Penn’s Role in Shaping AI
At a cross-disciplinary gathering at Amy Gutmann Hall, the Penn community celebrated the launch of the Penn AI Initiative with a panel discussing AI research at Penn.
Academic Entrepreneurship the Focus of Recent Speaker Series
Bryan presented on "Software as a Medical Device” and shared his journey co-founding Galileo CDS.
Penn’s Jake Brenner Develops State-of-the-art DNA-Delivery Technology
By safely delivering therapeutic DNA to cells, this technology has the potential to transform treatment for common chronic diseases.
Cesar de la Fuente’s AI Breakthroughs Could Help Predict the Next Pandemic
Recently, Dr. de la Fuente’s lab has been working on developing new antibiotics and exploring prehistoric proteins that could be repurposed to fight modern diseases
2025 President’s Innovation Prize Winner Announced
The team is developing a privacy-centric AI system to support eldercare by reducing staff burnout and addressing gaps in caregiving.
Veradermics Closes Series B Financing and Initiates Phase 2/3 Trial for Hair Loss
Veradermics is a late clinical-stage aesthetics and dermatology-focused biopharmaceutical company developing first-in-class therapeutics for common dermatologic conditions.
Vivodyne Weighs in on FDA Proposed Initiative
The FDA recently revealed a new initiative aimed at eliminating the need to test antibody therapeutics in animal models and replacing them with AI modelling or lab-grown human organoids.
Opus Genetics Celebrates Early Win for Retinal Gene Therapy in Pediatric Patient
According to the data, the 16-year-old patient, who was treated in February, showed "meaningful improvement in visual function."